Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Filip Janku Sells 30,000 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 30,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $21.42, for a total transaction of $642,600.00. Following the completion of the sale, the insider directly owned 59,992 shares of the company’s stock, valued at $1,285,028.64. The trade was a 33.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total value of $239,505.90.

Monte Rosa Therapeutics Price Performance

Shares of GLUE opened at $21.66 on Friday. The stock has a market capitalization of $1.83 billion, a PE ratio of -14.64 and a beta of 1.60. The business’s fifty day moving average price is $18.88 and its 200 day moving average price is $18.61. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. As a group, research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $30,000. Nisa Investment Advisors LLC grew its position in Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Monte Rosa Therapeutics in the fourth quarter valued at $63,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Monte Rosa Therapeutics in the third quarter worth $32,000. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GLUE has been the topic of a number of research reports. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Wells Fargo & Company lowered their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. increased their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Guggenheim decreased their price target on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.